Loading...
Market
What will be the next major milestone for Duvakitug by December 31, 2025?
2
Resolution / Starting Odds
Phase 3 trial completion • 25%
Regulatory approval • 25%
Commercial launch • 25%
Partnership or acquisition • 25%
Official announcements from Teva and Sanofi
Story
Teva and Sanofi's Duvakitug Shows Promise in Phase 2b Trial for IBD, Shares Surge
Dec 17, 2024, 03:45 PM
Teva Pharmaceutical Industries and Sanofi have announced positive results from a Phase 2b clinical trial named RELIEVE UCCD for their drug, Duvakitug, which targets ulcerative colitis and Crohn's disease. The trial showed that Duvakitug met its primary endpoints, with 36.2% of ulcerative colitis patients on a low dose and 47.8% on a high dose achieving clinical remission, compared to 20.45% on placebo. For Crohn's disease, 26.1% of patients on a low dose and 47.8% on a high dose achieved an endoscopic response, compared to 13% on placebo. The drug was well tolerated with no safety signals identified. Following these results, Teva's shares surged by nearly 20%, while Sanofi's shares climbed by almost 5%. The companies plan to initiate Phase 3 development pending regulatory discussions.
View original story
Similar markets
Achieves 50% cost reduction • 25%
Secures additional funding round • 25%
Integrates with 5 major AI platforms • 25%
Launches new REST API • 25%
Pass Turing Test • 25%
Perform complex task • 25%
Commercial sale • 25%
No significant milestone • 25%
Launches new product feature • 25%
Expands to international market • 25%
Secures additional funding • 25%
Partners with a major company • 25%
Publishes in Nature or Science • 25%
Partners with a top 10 pharmaceutical company • 25%
Releases a new version of Chai-1 • 25%
None of the above • 25%
Foundation dissolved • 25%
New projects announced • 25%
Leadership change • 25%
No significant changes • 25%
Phase 1 completion • 25%
Phase 2 initiation • 25%
Partnership announcement • 25%
Other milestone • 25%
Secures Series A funding • 25%
Announces major partnership • 25%
Publishes groundbreaking research • 25%
Other • 25%
Starts production of 1,000 Starships annually • 33%
Reaches serialized production of Falcon 9's second stage • 33%
Completes construction and begins operations • 34%
Launch of a commercial product • 25%
Partnership with a major tech company • 25%
Additional funding round • 25%
Other • 25%
Exoplanet Imaging • 25%
Galactic Observation • 25%
Dark Matter Research • 25%
Other • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Regulatory approval submission • 25%
No significant milestone • 25%
Cutting government waste • 25%
Eliminating regulations • 25%
Restructuring federal agencies • 25%
Other • 25%